Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Brand: Gardasil®
PBAC's latest decision on Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Recommended with restriction (2011). Considered for prevention of human papillomavirus (HPV) in males 12-13 years of age and a catch-up program over 2 years for Year 9 males.
PBAC outcome
Recommended with restriction
2011
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2011
Submissions
1
2011 → 2011
Eligible population
males aged 12-13 years and Year 9 males (catch-up program)
Therapy area
Other
Evidence base
RCT
Key trials
Protocol 020
Comparator
current female HPV vaccination
Economic model
CUA
ICER note
Base case ICER stated as a band. ICER increases to $45,000–$75,000/QALY when no growth of anal and oropharyngeal cancer is assumed after 2014.